Dr Reddy's share price jumped almost 4% during Wednesday’s trading session after Nuvama Institutional Equities, a brokerage firm, raised its rating on the stock from ‘Reduce’ to ‘Buy,’ setting a target price of ₹1,553. The brokerage noted that the expiration of the Revlimid patent in 2026 presents a considerable risk to Dr Reddy's earnings growth, as the medication accounts for …
Natco Pharma Ltd isn’t your run-of-the-mill pharmaceutical company. View Full Image Source: Investor Presentation Revlimid: A double-edged sword Revlimid, the blockbuster cancer drug, is the primary driver behind Natco’s financial performance in recent years. View Full Image Rajeev Nannapaneni is Vice Chairman/CEO at Natco Pharma Ltd. Risk of history repeating itself Natco’s journey is dotted with instances where its blockbuster …
Indian pharma companies have long been key providers of generic medicines to the US market, accounting for 47% of all generic prescriptions in 2022, according to a recent report by the IQVIA Institute. Branded for growth Mankind Pharma Ltd, which earns 91% of its revenue from its domestic business and has a prescriber penetration rate of almost 84% as of …
The news on the successful Completion of US FDA Inspection at Unit I & III of Aurobindo Pharma Ltd lifted investor sentiments and the share prices gained of Aurobindo Pharma gained more than 1% in morning trades on Monday, on a day when benchmark indices were trading in red. Aurobindo Pharma in its filing on the exchanges said that United …
